[關(guān)鍵詞]
[摘要]
目的 探討貝伐單抗聯(lián)合多西他賽治療晚期宮頸癌的臨床療效及安全性。方法 收集2011年4月-2016年4月于西安醫(yī)學(xué)院第二附屬醫(yī)院進(jìn)行治療的晚期宮頸癌患者75例作為研究對(duì)象進(jìn)行回顧性分析,按照治療方法的不同將其分為觀察組43例和對(duì)照組32例。對(duì)照組患者僅使用多西他賽治療,觀察組在此基礎(chǔ)上加用貝伐單抗。對(duì)兩組患者臨床療效、不良反應(yīng)、生活質(zhì)量以及藥物經(jīng)濟(jì)學(xué)進(jìn)行考察與比較。結(jié)果 觀察組總有效率和臨床控制率均顯著高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組患者在血液系統(tǒng)、消化系統(tǒng)及其他毒副反應(yīng)發(fā)生率方面均無顯著差異。觀察組生活質(zhì)量改善總有效率為83.72%,對(duì)照組為62.50%,觀察組顯著高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。觀察組平均治療費(fèi)用為(8.3±1.0)萬元,對(duì)照組為(1.8±0.6)萬元,觀察組顯著高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 貝伐單抗聯(lián)合多西他賽治療晚期宮頸癌臨床療效優(yōu)于多西紫杉醇單藥,但費(fèi)用高昂,需結(jié)合患者自身情況制定治療方案。
[Key word]
[Abstract]
Objective To explore the clinical efficacy and safety of bevacizumab combined with docetaxel in treatment of advanced cervix cancer. Methods Seventy-five patients with advanced cervix cancer accepted in our hospital from April 2011 to April 2016 were selected and divided into observation group with 43 cases and control group with 32 cases according to different treatment methods. Patients in control group were given docetaxel, and patients in observation group were combined with bevacizumab on the basis of control group. The clinical efficacy, adverse reactions, life quality and pharmacoeconomics of two groups were observed and compared. Results The total efficacy and clinical control rate of observation group were all higher than control group with statistically significance (P<0.05). The adverse reaction rate of two groups had no difference. Total efficacy of life quality improvement was 83.72%, which was obviously higher than control group 62.50% with statistically significance (P<0.05). The average cost of observation group was (83±10) thousands, of control group was (18±6) thousands. The cost of observation group was obviously higher than control group with statistically significance (P<0.05). Conclusion Using bevacizumab combined with docetaxel in treatment of advanced cervix cancer has better effect clinical but costs much than docetaxel. We should set on treatment according to patients' own situation.
[中圖分類號(hào)]
[基金項(xiàng)目]